Tag Archives: Liana Moussatos

Wedbush Reiterates a Buy Rating on Albireo Pharma (ALBO)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price target of $62.00. The company’s shares closed last Friday at $39.30. According to TipRanks.com, Moussatos is a 5-star analyst with

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Gilead Sciences (GILD – Research Report) with bullish sentiments. BioMarin Pharmaceutical (BMRN) Wedbush analyst Liana

Wedbush Thinks Allena Pharmaceuticals’ Stock is Going to Recover

Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) today and set a price target of $18.00. The company’s shares closed last Wednesday at $1.17, close to its 52-week low of $0.53. According to

Verona Pharma (VRNA) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $23.00. The company’s shares closed last Tuesday at $6.85. According to TipRanks.com, Moussatos is a

Wedbush Keeps Their Buy Rating on Aquestive Therapeutics (AQST)

In a report issued on August 28, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report), with a price target of $33.00. The company’s shares closed last Tuesday at $7.84. According to TipRanks.com, Moussatos

Axcella Health (AXLA) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $19.00. The company’s shares closed last Thursday at $5.16. According to TipRanks.com, Moussatos is a